+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Number-needed-to-treat analysis of droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Home
Publications
Number-needed-to-treat analysis of droxidopa in patients with symptomatic neurogenic orthostatic hypotension
Back Home
Number-needed-to-treat analysis of droxidopa in patients with symptomatic neurogenic orthostatic hypotension
2015 19th International Congress of Parkinson's Disease and Movement Disorders
Francois, C. | Rowse, G. | Hauser, H. | Hewitt, A. H. |
Volume: , Issue: , Pages: ,
The website uses cookies.
Learn More
Ok
